320 Hatch Dr.
7 articles with Notable Labs
There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.
Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, announced their partnership.
Notable , which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Dr. Thomas A. Bock to its board of directors. Bock is a recognized life science leader who built four entrepreneurial organizations that created major impact for both patients and investors, achieving leadership in their fields. He successfully spearheade
Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.
Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies
First peer-reviewed publication highlighting Notable’s platform published today in Blood Advances
It's no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
In Personalized Medicine Feasibility Study, Stanford Medical Center, With Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer Patients
With respect to accuracy, interim clinical data demonstrated both positive and negative predictive value average of 84 percent.